AU2019299152A1 - Method for producing diarylpyridine derivatives - Google Patents
Method for producing diarylpyridine derivatives Download PDFInfo
- Publication number
- AU2019299152A1 AU2019299152A1 AU2019299152A AU2019299152A AU2019299152A1 AU 2019299152 A1 AU2019299152 A1 AU 2019299152A1 AU 2019299152 A AU2019299152 A AU 2019299152A AU 2019299152 A AU2019299152 A AU 2019299152A AU 2019299152 A1 AU2019299152 A1 AU 2019299152A1
- Authority
- AU
- Australia
- Prior art keywords
- formula
- added
- contents
- compound represented
- stirred
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/12—1,4-Dioxanes; Hydrogenated 1,4-dioxanes not condensed with other rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
- B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
- B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
- B01J23/44—Palladium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018-127197 | 2018-07-04 | ||
| JP2018127197 | 2018-07-04 | ||
| PCT/JP2019/026395 WO2020009132A1 (ja) | 2018-07-04 | 2019-07-03 | ジアリールピリジン誘導体の製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019299152A1 true AU2019299152A1 (en) | 2021-03-04 |
| AU2019299152A2 AU2019299152A2 (en) | 2021-03-11 |
Family
ID=69059540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019299152A Abandoned AU2019299152A1 (en) | 2018-07-04 | 2019-07-03 | Method for producing diarylpyridine derivatives |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11999724B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3819296B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7337058B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112368271A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019299152A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3105328A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2925365T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL279070B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI840378B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020009132A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023090337A1 (cg-RX-API-DMAC7.html) | 2021-11-19 | 2023-05-25 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201404505PA (en) * | 2012-01-31 | 2014-10-30 | Daiichi Sankyo Co Ltd | Pyridone derivative |
| TWI723572B (zh) * | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| TWI796326B (zh) | 2017-03-24 | 2023-03-21 | 日商第一三共股份有限公司 | 含有ａｘｌ抑制劑與ｅｇｆｒ酪胺酸激酶抑制藥的醫藥品及其用途 |
-
2019
- 2019-07-01 TW TW108123125A patent/TWI840378B/zh not_active IP Right Cessation
- 2019-07-03 JP JP2020529019A patent/JP7337058B2/ja active Active
- 2019-07-03 WO PCT/JP2019/026395 patent/WO2020009132A1/ja not_active Ceased
- 2019-07-03 AU AU2019299152A patent/AU2019299152A1/en not_active Abandoned
- 2019-07-03 EP EP19831009.6A patent/EP3819296B1/en active Active
- 2019-07-03 US US17/252,469 patent/US11999724B2/en active Active
- 2019-07-03 CA CA3105328A patent/CA3105328A1/en active Pending
- 2019-07-03 ES ES19831009T patent/ES2925365T3/es active Active
- 2019-07-03 CN CN201980043226.0A patent/CN112368271A/zh active Pending
- 2019-07-03 IL IL279070A patent/IL279070B2/en unknown
-
2023
- 2023-08-22 JP JP2023134392A patent/JP2023159297A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202005962A (zh) | 2020-02-01 |
| US20210188823A1 (en) | 2021-06-24 |
| JP2023159297A (ja) | 2023-10-31 |
| ES2925365T3 (es) | 2022-10-17 |
| CA3105328A1 (en) | 2020-01-09 |
| IL279070B2 (en) | 2024-05-01 |
| JPWO2020009132A1 (ja) | 2021-07-08 |
| CN112368271A (zh) | 2021-02-12 |
| WO2020009132A1 (ja) | 2020-01-09 |
| EP3819296B1 (en) | 2022-06-29 |
| US11999724B2 (en) | 2024-06-04 |
| AU2019299152A2 (en) | 2021-03-11 |
| IL279070A (en) | 2021-01-31 |
| TWI840378B (zh) | 2024-05-01 |
| IL279070B1 (en) | 2024-01-01 |
| EP3819296A4 (en) | 2021-06-09 |
| EP3819296A1 (en) | 2021-05-12 |
| JP7337058B2 (ja) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114516867B (zh) | 一类含氧五元杂环化合物、合成方法、药物组合物及用途 | |
| ES2394472T3 (es) | Derivados de quinazolín-oxima como inhibidores de hsp90 | |
| AU2017364725B2 (en) | Method for producing triazolopyridine compound | |
| KR102566834B1 (ko) | 코판리십 및 그의 디히드로클로라이드 염의 합성 | |
| CA2757458A1 (en) | Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof | |
| TWI697494B (zh) | 科帕利普（ｃｏｐａｎｌｉｓｉｂ）及其二鹽酸鹽之合成 | |
| US20070203178A1 (en) | Crystalline solvates of apixaban | |
| AU2018236290A1 (en) | MK2 inhibitors, synthesis thereof, and intermediates thereto | |
| JP5730986B2 (ja) | プラスグレル塩の結晶性形態 | |
| BR112013023480B1 (pt) | Composto heterocíclico saturado contendo nitrogênio, seu uso e composição farmacêutica | |
| KR102183356B1 (ko) | Fgfr 억제제를 제조하기 위한 방법 | |
| AU2019299152A2 (en) | Method for producing diarylpyridine derivatives | |
| JP2017114875A (ja) | アルキニルケトン誘導体の製造方法 | |
| CN102264708B (zh) | 生产喹唑啉衍生物的方法 | |
| JP7068402B2 (ja) | チアゾール誘導体の製造方法 | |
| BR112019017309B1 (pt) | Método para a síntese de uma halo-olefina | |
| BRPI0708560A2 (pt) | processo para a preparação de um composto, e, composto | |
| AU2019218150B2 (en) | Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method therefor | |
| JP6165335B2 (ja) | ゲフィチニブの新規な結晶形およびその製造方法 | |
| CN111989331B (zh) | 2-[(2S)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1H-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3H)-酮的合成方法 | |
| JP2012516327A (ja) | カルボキシ含有ピラゾールアミド化合物を製造するための新規な方法 | |
| Hu et al. | An efficient synthesis of Erismodegib | |
| Zaleska et al. | Spectroscopic study of the keto-enol equilibrium of N-aryldiacetylthioacetamides and their reactivity | |
| KR20240089380A (ko) | 마보릭사포의 합성 및 그 중간체 | |
| JPH07242694A (ja) | トリアゾロプリンヌクレオシド誘導体及び該誘導体を製造するのに有用な合成中間体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 04 FEB 2021 |
|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |